Compare Synopsys, Inc. (SNPS) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synopsys, Inc. vs Sanofi SA — how do they compare? Synopsys, Inc. trades at $398.6 (market cap $75.36B), while Sanofi SA trades at $43.12 (market cap $103.41B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays a 5.65% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.
| SNPS | SNY | |
|---|---|---|
Market Cap | $75.36B | $103.41B |
Sector | Technology | Health |
52-Week High | $534.56 | $52.34 |
52-Week Low | $372.33 | $41.33 |
Enterprise Value | $82.59B | $123.44B |
Dividend Yield | — | 5.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synopsys (SNPS) trades at $392.03, down 0.46% on the day, with a bearish technical signal from moving averages but strong fundamental performance including three consecutive quarterly EPS beats. Revenue reached $7.05B in 2025 with an 11.43% net income margin, though valuation ratios like a P/E of 68.42 appear elevated. Recent news highlights its critical role in AI chip design and integration benefits from the Ansys acquisition.
The outlook is supported by Wall Street's bullish consensus with a $541.88 price target, but risks include high valuation sensitivity, competitive pressures in semiconductor software, and macroeconomic headwinds. Earnings growth and execution on raised 2026 guidance are key catalysts for upside.
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
